Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide

Next Previous
Trial Profile

Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Obesity; Pregnancy; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk

Most Recent Events

  • 09 Jan 2012 Actual initiation date (November 2006) added as reported by ClinicalTrials.gov.
  • 09 Jan 2012 Actual end date (Apr 2007) added as reported by ClinicalTrials.gov.
  • 09 Jan 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top